WO2015039612A8 - 抑制btk和/或jak3激酶活性的化合物 - Google Patents
抑制btk和/或jak3激酶活性的化合物 Download PDFInfo
- Publication number
- WO2015039612A8 WO2015039612A8 PCT/CN2014/086820 CN2014086820W WO2015039612A8 WO 2015039612 A8 WO2015039612 A8 WO 2015039612A8 CN 2014086820 W CN2014086820 W CN 2014086820W WO 2015039612 A8 WO2015039612 A8 WO 2015039612A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- btk
- compound
- jak3
- compound inhibiting
- inhibiting activities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2924362A CA2924362C (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of btk and/or jak3 kinases |
KR1020167009680A KR101879422B1 (ko) | 2013-09-18 | 2014-09-18 | Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물 |
EP14846251.8A EP3048105A4 (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of btk and/or jak3 kinases |
MX2016003582A MX368781B (es) | 2013-09-18 | 2014-09-18 | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. |
AU2014323777A AU2014323777C1 (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of BTK and/or JAK3 kinases |
SG11201601980XA SG11201601980XA (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of btk and/or jak3 kinases |
BR112016005881A BR112016005881A2 (pt) | 2013-09-18 | 2014-09-18 | composto, composição farmacêutica e uso do composto |
US15/022,248 US9840517B2 (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of BTK and/or JAK3 kinases |
NZ718728A NZ718728A (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of btk and/or jak3 kinases |
RU2016110755A RU2650512C2 (ru) | 2013-09-18 | 2014-09-18 | Соединение, ингибирующее активности киназ ВТК и/или JAK3 |
JP2016543306A JP6458039B2 (ja) | 2013-09-18 | 2014-09-18 | Btk及び/又はjak3キナーゼの活性を抑制する化合物 |
IL24461116A IL244611B (en) | 2013-09-18 | 2016-03-15 | Compounds containing compressed pyrimidine/4,2,1-triazine two-ring systems as inhibitors of jak3 and/or btk kinase activity |
PH12016500531A PH12016500531B1 (en) | 2013-09-18 | 2016-03-18 | Compound inhibiting activities of btk and/or jak3 kinases |
US15/799,315 US10273242B2 (en) | 2013-09-18 | 2017-10-31 | Compound inhibiting activities of BTK and/or JAK3 kinases |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310429844 | 2013-09-18 | ||
CN201310429844.3 | 2013-09-18 | ||
CN201310430071 | 2013-09-18 | ||
CN201310430071.0 | 2013-09-18 | ||
CN201310430761 | 2013-09-18 | ||
CN201310430761.6 | 2013-09-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/022,248 A-371-Of-International US9840517B2 (en) | 2013-09-18 | 2014-09-18 | Compound inhibiting activities of BTK and/or JAK3 kinases |
US15/799,315 Division US10273242B2 (en) | 2013-09-18 | 2017-10-31 | Compound inhibiting activities of BTK and/or JAK3 kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015039612A1 WO2015039612A1 (zh) | 2015-03-26 |
WO2015039612A8 true WO2015039612A8 (zh) | 2016-03-03 |
Family
ID=52366909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/086820 WO2015039612A1 (zh) | 2013-09-18 | 2014-09-18 | 抑制btk和/或jak3激酶活性的化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9840517B2 (zh) |
EP (1) | EP3048105A4 (zh) |
JP (1) | JP6458039B2 (zh) |
KR (1) | KR101879422B1 (zh) |
CN (3) | CN106083887B (zh) |
AU (1) | AU2014323777C1 (zh) |
BR (1) | BR112016005881A2 (zh) |
CA (1) | CA2924362C (zh) |
IL (1) | IL244611B (zh) |
MX (1) | MX368781B (zh) |
NZ (1) | NZ718728A (zh) |
PH (1) | PH12016500531B1 (zh) |
RU (1) | RU2650512C2 (zh) |
SG (1) | SG11201601980XA (zh) |
WO (1) | WO2015039612A1 (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015039612A1 (zh) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
CN110526912B (zh) | 2014-06-19 | 2023-02-14 | 武田药品工业株式会社 | 用于激酶抑制的杂芳基化合物 |
CN106188060A (zh) | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
JP6851367B2 (ja) * | 2015-08-13 | 2021-03-31 | 北京韓美薬品有限公司Beijing Hanmi Pharm. Co., Ltd. | Irak4阻害剤、及びその応用 |
KR102048719B1 (ko) * | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
WO2017205766A1 (en) * | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
EP3950691A1 (en) * | 2016-06-30 | 2022-02-09 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
CN107698603B (zh) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
KR102398659B1 (ko) * | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
CN110709402B (zh) * | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
CN107312006B (zh) * | 2017-06-28 | 2019-11-15 | 郑州大学第一附属医院 | 吡咯并嘧啶类衍生物及其应用 |
CN109206435B (zh) * | 2017-06-29 | 2020-09-08 | 中国医药研究开发中心有限公司 | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 |
PL3733673T3 (pl) * | 2017-12-28 | 2022-09-26 | Daewoong Pharmaceutical Co., Ltd. | Pochodna oksyfluoropiperydyny jako inhibitor kinazy |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
ES2962852T3 (es) | 2019-05-10 | 2024-03-21 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de los mismos |
FI3966207T3 (fi) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Autofagian fenyyliaminopyrimidiiniamidi-inhibiittoreita ja menetelmiä niiden käyttämiseksi |
CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN115244055A (zh) * | 2020-01-21 | 2022-10-25 | 江苏先声药业有限公司 | 嘧啶并五元环类衍生物及其应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3181162A1 (en) | 2020-06-05 | 2021-12-09 | Stephen W. Kaldor | Inhibitors of fibroblast growth factor receptor kinases |
WO2023220439A1 (en) * | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
JP2008013527A (ja) | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体 |
EP2081936B1 (en) * | 2006-11-03 | 2014-04-02 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
AU2008312624B2 (en) | 2007-10-18 | 2014-07-10 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
KR20110025224A (ko) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
US20110207736A1 (en) * | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
NZ627709A (en) * | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
EP2624698A4 (en) | 2010-10-08 | 2014-10-08 | Abbvie Inc | Furo [3,2-D] PYRIMIDINE COMPOUNDS |
SG2014014450A (en) * | 2011-09-22 | 2014-09-26 | Pfizer | Pyrrolopyrimidine and purine derivatives |
AU2014229468A1 (en) * | 2013-03-14 | 2015-09-03 | Pfizer Inc. | Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer |
WO2015039612A1 (zh) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
UA115388C2 (uk) * | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
DK3318565T3 (da) * | 2013-12-05 | 2021-05-25 | Pfizer | Pyrrolo[2,3-D]pyrimidinyl-, pyrrolo[2,3-B]pyrazinyl- og pyrrolo[2,3-D]pyridinylacrylamider |
-
2014
- 2014-09-18 WO PCT/CN2014/086820 patent/WO2015039612A1/zh active Application Filing
- 2014-09-18 MX MX2016003582A patent/MX368781B/es active IP Right Grant
- 2014-09-18 CN CN201610412999.XA patent/CN106083887B/zh active Active
- 2014-09-18 JP JP2016543306A patent/JP6458039B2/ja active Active
- 2014-09-18 CN CN201610421223.4A patent/CN106065017B/zh active Active
- 2014-09-18 EP EP14846251.8A patent/EP3048105A4/en not_active Withdrawn
- 2014-09-18 AU AU2014323777A patent/AU2014323777C1/en active Active
- 2014-09-18 CN CN201410478741.0A patent/CN104311573B/zh active Active
- 2014-09-18 US US15/022,248 patent/US9840517B2/en active Active
- 2014-09-18 KR KR1020167009680A patent/KR101879422B1/ko active IP Right Grant
- 2014-09-18 NZ NZ718728A patent/NZ718728A/en unknown
- 2014-09-18 CA CA2924362A patent/CA2924362C/en active Active
- 2014-09-18 RU RU2016110755A patent/RU2650512C2/ru active
- 2014-09-18 SG SG11201601980XA patent/SG11201601980XA/en unknown
- 2014-09-18 BR BR112016005881A patent/BR112016005881A2/pt not_active IP Right Cessation
-
2016
- 2016-03-15 IL IL24461116A patent/IL244611B/en active IP Right Grant
- 2016-03-18 PH PH12016500531A patent/PH12016500531B1/en unknown
-
2017
- 2017-10-31 US US15/799,315 patent/US10273242B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015039612A8 (zh) | 抑制btk和/或jak3激酶活性的化合物 | |
SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
GEP201706748B (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
WO2018226622A8 (en) | Compounds for treating huntington's disease | |
CA2871471C (en) | Dna-pk inhibitors | |
CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
WO2016172134A3 (en) | Novel compounds | |
GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
WO2016109217A3 (en) | Btk inhibitors | |
MX2018007075A (es) | Compuestos policiclicos como inhibidores de tirosina quinasa de bruton. | |
WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
PH12015502365A1 (en) | Bace1 inhibitors | |
SG10201903621SA (en) | Tricyclic atropisomer compounds | |
CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14846251 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2924362 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 244611 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15022248 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016543306 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/003582 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016005881 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2014846251 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014846251 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167009680 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201602517 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2016110755 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014323777 Country of ref document: AU Date of ref document: 20140918 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016005881 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160317 |